Phase 3 Head and Neck Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose and throat) that has come back after previous treatment.
• People whose cancer has come back at a specific stage — either growing into certain nearby structures or reaching certain sizes, as classified by a standard cancer staging system (confirm with trial site for exact staging details).
• People whose cancer has not spread to distant parts of the body.
• People whose lymph nodes in the neck area can be treated effectively with local treatment.
• People aged between 18 and 75 years old.
• People who have signed the consent forms agreeing to take part in the trial.
• People whose cancer returned at least 6 months after completing their original radiation treatment.
• People who have had only one course of radiotherapy in the past.
• People whose major organs (such as heart, liver, and kidneys) are functioning well enough to tolerate treatment.
• People who are well enough to undergo surgery, chemotherapy, and immunotherapy, as measured by a standard fitness scale (ECOG score of 0–2).

Who may not be able to join:

• People who are already taking part in another interventional clinical trial.
• People who have other serious illnesses that are not well controlled and could interfere with treatment.
• People who have had another cancer within the past 5 years (though some fully treated minor skin cancers or early-stage cervical conditions may be exceptions — confirm with trial site).
• People for whom surgery is not considered safe or suitable.
• People who have a serious autoimmune disease.
• People who are currently taking immunosuppressive medications or high-dose steroid treatments, or who have been doing so within the 2 weeks before the first treatment dose.
• People who have had a severe allergic reaction to monoclonal antibody treatments in the past.
• People who have a history of radioactive particle implant treatment (a specific type of internal radiation therapy).
• People who have received a live vaccine within 4 weeks before the start of the trial, or who may need one during the study period.
• People who are currently pregnant or breastfeeding.
• People whom the trial researchers consider unsuitable for other reasons (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.